Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Biomarcadores para diagnóstico de enfermedad inflamatoria intestinal

Resultados 137 results.
LastUpdate Updated on 22/05/2025 [07:14:00]
pdfxls
Solicitudes publicadas en los últimos 150 días / Applications published in the last 150 days
Results 1 to 25 of 137 nextPage  

PHARMACEUTICAL COMPOSITION FOR TREATING COLITIS OR COLORECTAL CANCER COMPRISING COLON-TARGETED S100A8/A9-DERIVED SPECIFIC PEPTIDE

Publication No.:  US2025154215A1 15/05/2025
Applicant: 
INDUSTRY UNIV COOPERATION FOUNDATION HANYANG UNIV ERICA CAMPUS [KR]
Industry-University Cooperation Foundation Hanyang University ERICA Campus

Absstract of: US2025154215A1

The present invention relates to a dual PRR-inhibiting peptide system consisting of TLR4- and RAGE-inhibiting motifs derived from S100A8 and S100A9 and conjugated with a CT peptide for colon-specific delivery. In human-derived monocyte THP-1 and mouse bone marrow-derived macrophages (BMDMs), S100A8/A9-derived peptides including TLR4 and RAGE-interacting motifs inhibit the binding of S100 to TLR4 or RAGE and the activation of the NLRP3 inflammasome in a dose-dependent manner. When the peptide according to the present invention is injected into mouse models of acute and chronic colitis, survival is significantly increased, and pathological damage to the colon is alleviated. In a mouse model of colitis-related colorectal cancer, when the peptide according to the present invention is injected, body weight is increased, tumor burden in the distal colon is decreased, and histological colon damage is significantly alleviated. When the peptide according to the present invention is injected into an oxaliplatin-resistant CRC xenograft mouse model, EMT-associated markers are reduced in tumor tissues and tumor growth is significantly inhibited.

Method for detecting and subtyping inflammatory intestinal diseases

Publication No.:  US2025154591A1 15/05/2025
Applicant: 
AABO AKADEMI [FI]
\u00C5bo Akademi
FI_20225151_A1

Absstract of: US2025154591A1

The present invention is related to a method for determining or confirming chronic inflammatory intestinal disease or a risk thereof in a subject. The method comprises detecting the presence of keratin 7 (K7) mRNA or protein in a biological sample obtained from a subject.

FLAGELLIN EPITOPE PEPTIDES AND USES THEREOF

Publication No.:  AU2023364180A1 15/05/2025
Applicant: 
THE UAB RES FOUNDATION
THE UAB RESEARCH FOUNDATION
AU_2023364180_PA

Absstract of: AU2023364180A1

Provided herein is a peptide array comprising a plurality of flagellin peptides corresponding to highly conserved peptide regions. For example, the peptide array comprises a plurality of

CROSS LINKED COLLAGEN TYPE V ASSAY

Publication No.:  EP4551599A1 14/05/2025
Applicant: 
NORDIC BIOSCIENCE AS [DK]
Nordic Bioscience A/S
KR_20250034424_PA

Absstract of: CN119546632A

The present invention relates to a sandwich immunoassay for determining cross-linked collagen type V in a biological sample, and its use in identifying patients suffering from conditions associated with fibrosis, such as ankylosing spondylitis, inflammatory bowel disease, psoriasis and atopic dermatitis. The invention also relates to a kit for performing a sandwich immunoassay.

METHOD FOR BOWEL PREPARATION

Publication No.:  US2025144219A1 08/05/2025
Applicant: 
MSM INNOVATIONS INC [US]
MSM Innovations, Inc
JP_2023182719_PA

Absstract of: US2025144219A1

The present invention provides methods for facilitating cleansing of the gastrointestinal tract of a patient prior to a diagnostic, surgical or therapeutic procedure. The methods can improve patient compliance, and thus, efficacy of the preparation. Specifically, the present methods make the gastrointestinal tract preparation composition palatable for the patient to consume. For example, for a patient preparing to undergo colonoscopy, the present methods make the bowel preparation solution taste significantly less salty.

DETERMINING WHETHER AN IBD PATIENT WILL RESPOND TO 5-ASA THERAPY

Publication No.:  US2025146074A1 08/05/2025
Applicant: 
THE GENERAL HOSPITAL CORP [US]
PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US]
THE BRIGHAM AND WOMENSS HOSPITAL INC [US]
The General Hospital Corporation,
President and Fellows of Harvard College,
The Brigham and Womens's Hospital, Inc

Absstract of: US2025146074A1

The invention relates to a method of determining whether a patient diagnosed with inflammatory bowel disease (will respond to 5-ASA therapy which includes the steps of: obtaining a stool sample from the patient, analyzing the sample for the presence of microbial acetyltransferase genes capable of converting 5-ASA to the clinically ineffective N-acetyl 5-ASA, if microbial acetyltransferase genes are not present in the sample, the patient will respond to 5-ASA therapy and such therapy should be administered; if microbial acetyltransferase genes are present in the sample, the patient will not respond to 5-ASA therapy and a second line therapy should be administered.

METHODS AND USES OF INFLAMMATORY BOWEL DISEASE BIOMARKERS

Publication No.:  US2025146075A1 08/05/2025
Applicant: 
WASHINGTON UNIV [US]
Washington University
US_2023313305_PA

Absstract of: US2025146075A1

Among the various aspects of the present disclosure is the provision of methods of diagnosing and treating inflammatory bowel disease (IBD) including ulcerative colitis (UC) or Crohn's disease (CD). In particular, the present disclosure provides in part a panel of IBD biomarkers useful in diagnosing and making treatment decisions. In addition, the present disclosure provides methods of treating IBD with a plasminogen activator inhibitor-1 (PAI-1) inhibitor or tissue plasminogen activator (tPA).

Method for inflammatory bowel disease model using patient-derived intestinal organoids and use thereof

Publication No.:  KR20250058951A 02/05/2025
Applicant: 
한국화학연구원연세대학교산학협력단
KR_20250058951_PA

Absstract of: WO2025089672A1

The present invention relates to inflammatory bowel disease model production using patient-derived intestinal organoids, and use thereof, wherein the inflammatory bowel disease model produced by an optimized production method for inflammatory bowel disease model production can be used as a patient-customized bowel disease model by constructing an evaluation method for inflammatory bowel disease drugs.

METHOD FOR PROVIDING INFORMATION ON ULCERATIVE COLITIS AND DEVICE USING SAME

Publication No.:  WO2025089884A1 01/05/2025
Applicant: 
INDUSTRY ACADEMIC COOPERATION FOUNDATION YONSEI UNIV [KR]
SEOUL NATIONAL UNIV HOSPITAL [KR]
SAMSUNG LIFE PUBLIC WELFARE FOUND [KR]
SAMSUNG MEDICAL FOUND [KR]
UNIV OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION [KR]
THE ASAN FOUND [KR]
KOREA UNIV RESEARCH AND BUSINESS FOUNDATION [KR]
INDUSTRY ACADEMIC COOPERATION FOUNDATION DANKOOK UNIV [KR]
\uC5F0\uC138\uB300\uD559\uAD50 \uC0B0\uD559\uD611\uB825\uB2E8,
\uC11C\uC6B8\uB300\uD559\uAD50\uBCD1\uC6D0,
\uC0AC\uD68C\uBCF5\uC9C0\uBC95\uC778 \uC0BC\uC131\uC0DD\uBA85\uACF5\uC775\uC7AC\uB2E8,
(\uC758)\uC0BC\uC131\uC758\uB8CC\uC7AC\uB2E8,
\uC6B8\uC0B0\uB300\uD559\uAD50 \uC0B0\uD559\uD611\uB825\uB2E8,
\uC7AC\uB2E8\uBC95\uC778 \uC544\uC0B0\uC0AC\uD68C\uBCF5\uC9C0\uC7AC\uB2E8,
\uACE0\uB824\uB300\uD559\uAD50 \uC0B0\uD559\uD611\uB825\uB2E8,
\uB2E8\uAD6D\uB300\uD559\uAD50 \uC0B0\uD559\uD611\uB825\uB2E8
WO_2025089884_PA

Absstract of: WO2025089884A1

The present specification provides a method for providing information on ulcerative colitis by means of a processor, the method comprising: a step for receiving a Korean Ulcerative Colitis-Specific Questionnaire (K-UCSQ) score for an individual; and a step for determining an inflammatory bowel disease prognosis for the individual on the basis of the received K-UCSQ score.

INFLAMMATORY BOWEL DISEASE MODEL PRODUCTION USING PATIENT-DERIVED INTESTINAL ORGANOIDS, AND USE THEREOF

Publication No.:  WO2025089672A1 01/05/2025
Applicant: 
KOREA RESEARCH INSTITUTE OF CHEMICAL TECH [KR]
UIF UNIV INDUSTRY FOUNDATION YONSEI UNIV [KR]
\uD55C\uAD6D\uD654\uD559\uC5F0\uAD6C\uC6D0,
\uC5F0\uC138\uB300\uD559\uAD50 \uC0B0\uD559\uD611\uB825\uB2E8
WO_2025089672_PA

Absstract of: WO2025089672A1

The present invention relates to inflammatory bowel disease model production using patient-derived intestinal organoids, and use thereof, wherein the inflammatory bowel disease model produced by an optimized production method for inflammatory bowel disease model production can be used as a patient-customized bowel disease model by constructing an evaluation method for inflammatory bowel disease drugs.

METHODS AND COMPOSITIONS FOR THE TREATMENT OF ULCERATIVE COLITIS

Publication No.:  WO2025085674A1 24/04/2025
Applicant: 
BACAINN THERAPEUTICS INC [US]
BACAINN THERAPEUTICS, INC
WO_2025085674_PA

Absstract of: WO2025085674A1

In one aspect, the present disclosure provides a method for selecting a subject having ulcerative colitis for treatment with ADS051, or a pharmaceutically acceptable salt thereof, the method comprising: (a) measuring MRP2 seRNA in a stool sample obtained from the subject; and (b) selecting the subject for treatment when the level of MRP2 seRNA in the stool sample exceeds a threshold value. In some embodiments, the subject has moderate or severe ulcerative colitis.

METHODS OF TREATING A PATIENT WITH AN INFLAMMATORY BOWEL DISEASE

Publication No.:  WO2025085928A1 24/04/2025
Applicant: 
ODYSSEY THERAPEUTICS INC [US]
ODYSSEY THERAPEUTICS, INC
WO_2025085928_PA

Absstract of: WO2025085928A1

This disclosure relates generally to methods for treating an inflammatory bowel disease ("IBD", e.g., Crohn's disease or ulcerative colitis) in a patient. More particularly, this disclosure relates to methods for selecting a therapy for treating a patient suffering from an IBD. In embodiments, the foregoing can also be used to assess the severity of the IBD. The predictive aspects of said methods can facilitate and expedite the identification and stratification of IBD patient populations that are responsive to treatment with a RIPK2 inhibitor. The foregoing methods can further include treating the IBD by administering a RIPK2 inhibitor to the patient.

DIAGNOSIS AND TREATMENT OF DISEASES AND CONDITIONS OF THE INTESTINAL TRACT

Publication No.:  US2025129422A1 24/04/2025
Applicant: 
FLAGSHIP PIONEERING INNOVATIONS VI LLC [US]
Flagship Pioneering Innovations VI, LLC
WO_2023049839_A1

Absstract of: US2025129422A1

The invention relates to methods of monitoring treatment response, disease resolution, and disease progression in subjects having inflammatory bowel disease (IBD).

NOVEL INFLAMMATORY DISEASE TREATMENT AGENT AND SCREENING METHOD FOR SAME

Publication No.:  EP4541373A1 23/04/2025
Applicant: 
UNIV OSAKA [JP]
NATIONAL UNIV CORPORATION UNIV OF TOYAMA [JP]
OSAKA UNIVERSITY,
National University Corporation University Of Toyama
EP_4541373_A1

Absstract of: EP4541373A1

The present invention provides a therapeutic agent for sepsis and/or septic shock, comprising, as an active ingredient, a compound capable of suppressing phosphorylation of threonine at position 749 in human STAT1; a method for screening for a candidate compound serving as an active ingredient of a therapeutic agent for sepsis and/or septic shock, the method comprising selecting a compound capable of suppressing phosphorylation of threonine at position 749 in human STAT1; a therapeutic agent for colitis, comprising, as an active ingredient, a compound capable of promoting phosphorylation of threonine at position 749 in human STAT1; a method for screening for a candidate compound serving as an active ingredient of a therapeutic agent for colitis, the method comprising selecting a compound capable of promoting phosphorylation of threonine at position 749 in human STAT1; a therapeutic agent for systemic lupus erythematosus, comprising, as an active ingredient, a compound capable of inhibiting human STAT1; and a method for screening for a candidate compound serving as an active ingredient of a therapeutic agent for systemic lupus erythematosus, the method comprising selecting a compound capable of inhibiting human STAT1.

DIAGNOSIS AND TREATMENT OF DISEASES AND CONDITIONS OF THE INTESTINAL TRACT

Publication No.:  US2025122569A1 17/04/2025
Applicant: 
FLAGSHIP PIONEERING INNOVATIONS VI LLC [US]
Flagship Pioneering Innovations VI, LLC
US_2025122569_PA

Absstract of: US2025122569A1

The invention relates to methods of predicting a patient's responsiveness to treatment (e.g., vedolizumab treatment) for inflammatory bowel disease (IBD).

THERAPEUTIC DRUG FOR INFLAMMATORY DISEASES, AND SCREENING METHOD FOR THERAPEUTIC DRUG

Publication No.:  WO2025079348A1 17/04/2025
Applicant: 
TOHOKU UNIV [JP]
\u56FD\u7ACB\u5927\u5B66\u6CD5\u4EBA\u6771\u5317\u5927\u5B66
WO_2025079348_PA

Absstract of: WO2025079348A1

It has been revealed that, from an analysis of the mechanism regarding the action of sulfasalazine which is a therapeutic drug for inflammatory bowel disease, an anti-inflammatory action occurs by increasing intracellular glutamate. As a result of a detailed analysis, it has been revealed that a glutamine synthetase inhibitor or an xCT inhibitor which increases intracellular glutamate has a therapeutic effect on inflammatory bowel disease. Further, it is considered that a compound that suppresses expression of a glutamine synthesis inhibiting enzyme or xCT also has a therapeutic effect. An xCT inhibitor or a glutamine synthetase inhibitor is useful as a prophylactic/therapeutic drug that is for inflammatory diseases, particularly inflammatory bowel disease, and that has no serious side effects such as immunosuppression.

TL1A ASSOCIATED ANTIBODY COMPOSITIONS AND METHODS OF USE

Publication No.:  WO2025076081A1 10/04/2025
Applicant: 
ABSCI CORP [US]
ABSCI CORPORATION
WO_2025076081_A1

Absstract of: WO2025076081A1

The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1 A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.

COMPOSITIONS AND METHODS FOR SELECTING A SUBJECT FOR INFLAMMATORY BOWEL DISEASE TREATMENT

Publication No.:  WO2025076414A1 10/04/2025
Applicant: 
THE CHILDRENS MEDICAL CENTER CORP [US]
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI [US]
SNAPPER SCOTT [US]
COLLEN LAUREN [US]
SCHADT ERIC [US]
ARGMANN CARMEN [US]
BECKMANN NOAM [US]
THE CHILDREN'S MEDICAL CENTER CORPORATION,
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI,
SNAPPER, Scott,
COLLEN, Lauren,
SCHADT, Eric,
ARGMANN, Carmen,
BECKMANN, Noam
WO_2025076414_PA

Absstract of: WO2025076414A1

The disclosure provides methods for predicting response in a subject having IBD to anti-IL12 and/or anti-IL23-based therapies, and selecting an effective therapy.

POINT-OF-CARE TEST DIAGNOSTIC MARKERS AND ADJUVANT TREATMENTS FOR GASTROINTESTINAL DISEASES

Publication No.:  WO2025075714A1 10/04/2025
Applicant: 
ROWAN UNIV [US]
THE COOPER HEALTH SYSTEM [US]
ROWAN UNIVERSITY,
THE COOPER HEALTH SYSTEM
WO_2025075714_A1

Absstract of: WO2025075714A1

Described herein is a method of diagnosing and/or treating irritable bowel syndrome (IBS) in a subject. The method comprises determining a fatty acid profile in a stool sample of the subject; and comparing the fatty acid profile with a first reference profile indicating an absence of IBS or a second reference profile indicating IBS. Also described herein is a composition for treating IBS, which comprises two or more of a Monoglobaceae bacterium, a Lachnospiraceae bacterium; and a Ruminococcaceae bacterium, as well as a method of treating IBS using the same.

SYNBIOTIC SUPPLEMENT FORMULATION

Publication No.:  US2025114413A1 10/04/2025
Applicant: 
MEDISYN BIO INC [US]
MEDISYN-BIO INC

Absstract of: US2025114413A1

The present disclosure relates to a formulation for supporting the growth or maintenance of bacteria in the gastrointestinal tract of an animal. Provided is the use of at least one human milk oligosaccharide in combination with pre-biotics and probiotic strains of bacteria for the manufacture of a food composition, pharmaceutical composition, food or dietary supplement, for the selective stimulation of beneficial bacteria in the gastrointestinal tract in context of a disease condition. Also provided is a synbiotic formulation comprising living beneficial bacteria formulated with at least one human milk oligosaccharide in combination with pre-biotics. In particular, synbiotic formulation is used for improving clinical biomarkers in diseases especially Crohn's disease.

ULCERATIVE COLITIS TREATMENTS IN SELECTED PATIENTS

Publication No.:  EP4531861A1 09/04/2025
Applicant: 
THERIVA BIOLOGICS INC [US]
Theriva Biologics, Inc
AU_2023276693_PA

Absstract of: AU2023276693A1

The present disclosure relates, inter alia, to methods of treating ulcerative colitis with therapeutic intestinal alkaline phosphatases.

TL1A ASSOCIATED ANTIBODY COMPOSITIONS AND METHODS OF USE

Publication No.:  US2025109209A1 03/04/2025
Applicant: 
ABSCI CORP [US]
ABSCI Corporation
US_2025109209_PA

Absstract of: US2025109209A1

The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.

TL1A ASSOCIATED ANTIBODY COMPOSITIONS AND METHODS OF USE

Publication No.:  US2025109210A1 03/04/2025
Applicant: 
ABSCI CORP [US]
ABSCI CORPORATION
US_2025109210_PA

Absstract of: US2025109210A1

The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.

COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE

Publication No.:  WO2025064645A1 27/03/2025
Applicant: 
FLAGSHIP PIONEERING INNOVATIONS VI LLC [US]
FLAGSHIP PIONEERING INNOVATIONS VI, LLC

Absstract of: WO2025064645A1

The invention relates to diagnostic and therapeutic methods for inflammatory bowel disease (IBD) and to physiologically acceptable compositions of isolated bacterial strains, lysates thereof, and supernatants therefrom for use in treating IBD.

SYSTEM AND METHOD FOR DIAGNOSING INFLAMMATORY BOWEL DISEASE STATE AND SEVERITY

Nº publicación: WO2025064813A1 27/03/2025

Applicant:

THE CLEVELAND CLINIC FOUND [US]
THE CLEVELAND CLINIC FOUNDATION

US_2025104866_PA

Absstract of: WO2025064813A1

A method for determining a pathological parameter (e.g., a microvilli length (MVL)) of a subject is used to determine a therapeutic response for treatment of the subject. The method includes receiving a pathology image of the subject, identifying a pathological feature and determining a parameter of that feature (e.g., MVL), and determining an aggregate parameter. The pathology image may be pre-processed and/or segmented into regions of interest. The entire pathology image and/or the segmented regions may be subject to feature annotation.

traducir